Mesavancol (Mesalazine)

Mesalazine acts locally in the gastrointestinal tract by blocking cyclooxygenase and lipoxygenase enzymes, which lowers the production of prostaglandins and leukotrienes. This reduction in inflammatory mediators diminishes leukocyte infiltration and cytokine release, thereby decreasing mucosal inflammation characteristic of ulcerative colitis and Crohn’s disease.

The specific dose of Mesavancol is determined by the prescribing clinician based on the individual’s disease severity, location, and response to therapy. Healthcare professionals tailor the regimen to each patient, and the exact dosage should be obtained from the treating physician’s prescription.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mesavancol. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mesavancol delivers mesalazine, the same active moiety found in other 5‑ASA products such as Asacol and Pentasa. Differences lie mainly in formulation, release characteristics, and dosing frequency. Clinical efficacy is comparable, but individual tolerability and convenience may vary, so clinicians choose the product that best fits a patient’s lifestyle and therapeutic needs.

Mesavancol should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it away from direct sunlight or heat sources to maintain stability and potency throughout its shelf life.

Mesavancol is taken orally, usually in tablet or granule form, as directed by the prescribing physician. The medication should be swallowed with water and may be taken with or without food, depending on the specific product instructions and patient tolerance.

Serious adverse events, although rare, include myocarditis, pancreatitis, severe allergic reactions such as anaphylaxis, blood disorders like agranulocytosis, and significant renal or hepatic impairment. Patients should be monitored regularly, and any signs of these conditions warrant immediate medical evaluation.

Mesavancol is contraindicated in individuals with a known hypersensitivity to mesalazine, other 5‑ASA compounds, or any excipients in the formulation. It should also be avoided in patients with severe renal or hepatic dysfunction where the risk outweighs potential benefit, and in those for whom alternative therapies are more appropriate.